Tickers

CHE — Ticker Eval done nvidia/nemotron-3-ultra-550b-a55b:free

Requested 2026-09-21 11:55:11.737290 UTC · finished 2026-09-21 11:59:57.360499 UTC

1. Composite Trajectory Verdict

Given CHE's asset-light, service-based model with high cash conversion, the income statement and cash flow statement carry the most weight for assessing operating performance, while the balance sheet reflects capital allocation choices.

Composite Trajectory: Mixed

Annual results for 2025 show clear deterioration versus 2024: consolidated revenue grew 4.1% but net income fell 12.2%, operating income fell 7.7%, and gross margin excluding depreciation compressed to 32.5% from 35.1% (10-K 2025, Consolidated Statements of Operations; MD&A). However, the most recent quarterly data (Q2 2026 vs Q2 2025) show improvement: revenue rose 8.8%, net income rose 29%, and consolidated gross margin expanded to 32.9% from 29.8% (10-Q 2026-06-30, MD&A). Cash flow from operations declined annually in 2025 but was roughly flat year-over-year in the first half of 2026. The balance sheet has deteriorated consistently: cash has fallen from $264M (2023) to $40M (June 2026), long-term debt has risen from $0 to $140M, and the current ratio dropped from 1.4 to 1.1 (10-K 2025, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets). These opposing trends across statements and timeframes yield a mixed composite trajectory.

2. Red Flags

  • Medicare cap liability volatility: VITAS recorded a $27.2M Medicare cap reduction in 2025 versus $8.4M in 2024 and $8.0M in 2023 (10-K 2025, MD&A), but the liability dropped to $0.5M in Q2 2026 from $16.4M in Q2 2025 (10-Q 2026-06-30, MD&A), creating earnings unpredictability.
  • Roto-Rooter implicit price concessions surge: Implicit price concessions and credit memos jumped 41.8% to $38.0M in 2025 from $26.8M in 2024, primarily in water restoration (10-K 2025, MD&A).
  • Three-year gross margin compression: Consolidated gross margin excluding depreciation fell from 35.3% (2023) to 35.1% (2024) to 32.5% (2025) (10-K 2025, MD&A).
  • Roto-Rooter net income declining for three consecutive years: $188.2M (2023) → $160.0M (2024) → $135.5M (2025) (10-K 2025, Consolidating Statements of Income).
  • Share repurchases exceeding free cash flow: In 2025, $431.5M of buybacks vs. $325.5M of operating cash flow after capex; in 2024, $361.4M vs. $368.0M (10-K 2025, Cash Flow).
  • Liquidity and leverage shift: Cash fell from $178.4M (Dec 2024) to $74.5M (Dec 2025) to $40.2M (June 2026) while long-term debt rose from $0 to $140M (10-K 2025, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets). Current ratio declined from 1.4 to 1.1 (10-K 2025, Liquidity and Capital Resources).
  • Unquantified cybersecurity litigation: A data breach in October 2025 triggered multiple class actions with no estimable loss range (10-K 2025, Note 18).
  • Recurring legal settlements: $3.1M in 2025, $0 in 2024, $2.1M in 2023 (10-K 2025, Note 20).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual GAAP net income fell 12.2% in 2025 to $265.2M from $302.0M in 2024, after rising 10.8% in 2024 from $272.5M in 2023 (10-K 2025, Consolidated Statements of Operations). Operating income followed a similar pattern: $338.2M (2025) vs. $366.5M (2024) vs. $340.6M (2023). VITAS segment net income declined 5.9% in 2025 to $204.0M, while Roto-Rooter segment net income fell 15.3% to $135.5M (10-K 2025, Consolidating Statements of Income). Conversely, Q2 2026 showed strong year-over-year improvement: consolidated net income rose 29% to $67.7M, VITAS net income surged 59% to $60.9M, and Roto-Rooter net income was essentially flat at $31.9M (10-Q 2026-06-30, Consolidating Statements of Income). Six-month 2026 net income increased 7.8% to $134.0M (10-Q 2026-06-30, MD&A). The divergence between full-year 2025 weakness and first-half 2026 strength, driven largely by a sharp reduction in Medicare cap expense, supports a mixed assessment.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Annual operating cash flow peaked at $417.5M in 2024, up 26% from $330.3M in 2023, but declined 7% to $388.3M in 2025 (10-K 2025, Cash Flow). Free cash flow (operating cash flow less capex) followed: $273.4M (2023) → $368.0M (2024) → $325.5M (2025). In the first half of 2026, management reported operating cash flow increased only $1.7M year-over-year (10-Q 2026-06-30, Liquidity and Capital Resources), implying rough stability. However, the absence of detailed quarterly cash flow statements for Q2 2026, Q1 2026, Q3 2025, and Q2 2025 in the provided filings prevents a robust quarterly trend analysis. The annual series shows a rise then fall, while the latest partial-year data point suggests stabilization, resulting in a mixed trajectory.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

The balance sheet has weakened across each reported period. Cash and equivalents declined from $264.0M (Dec 2023) to $178.4M (Dec 2024) to $74.5M (Dec 2025) to $40.2M (June 2026) (10-K 2025, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets). Long-term debt, which was zero at Dec 2024 and Dec 2025, appeared at $140.0M by June 2026 due to acquisitions and share repurchases (10-Q 2026-06-30, MD&A). Total stockholders' equity fell from $1,119.0M (Dec 2024) to $979.4M (Dec 2025) as treasury stock grew from $3,127M to $3,608M (10-K 2025, Consolidated Balance Sheets). The current ratio dropped from 1.4 to 1.1 over the same annual period (10-K 2025, Liquidity and Capital Resources). Goodwill increased to $667.0M from $585.0M in 2023, reflecting acquisition activity (10-K 2025, Note 7). These trends are uniformly negative over the available periods.

6. Data Gaps

  • Quarterly cash flow statements for Q2 2026, Q1 2026, Q3 2025, and Q2 2025 (only net change in operating cash flow for H1 2026 is disclosed).
  • Full consolidated balance sheet for Dec 2023 (XBRL data truncated in 10-K).
  • Segment operating income breakdown for quarters prior to Q2 2026.
  • Nine-month 2025 results (10-Q for Sep 30, 2025 not provided in filings).
  • Q1 2026 results (10-Q for Mar 31, 2026 not provided in filings).
  • Detailed breakdown of "Other" revenue and expense line items for Roto-Rooter in quarterly periods.
Long US-equity 13F disclosures only · up to 45-day reporting lag · sells = reduce/avoid, not short. JSON: /api/signals · /api/funds · /api/status